Open AccessRetrospective evaluation of hairy cell leukemia patients treated with 3 different first-line treatment modalities in the last two decades: a single center experience
Author(s) -
Şeniz Öngören,
Ahmet Emre Eşkazan,
Selin Berk,
Tuğrul Elverdi,
Ayşe Salihoğlu,
Muhlis Cem Ar,
Zafer Başlar,
Yıldız Aydın,
Nükhet Tüzüner,
Teoman Soysal
Publication year - 2017
Publication title -
turkish journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.351
H-Index - 16
ISSN - 1300-7777
DOI - 10.4274/tjh.2017.0443
Subject(s) - medicine , single center , modalities , center (category theory) , retrospective cohort study , treatment modality , medical physics , surgery , social science , chemistry , sociology , crystallography
Objective: In this study, we retrospectively analyzed the clinical outcome, treatment responses, infectious complications, and survival rates of 71 hairy cell leukemia (HCL) cases. \udMaterials and Methods: Sixty-seven patients received a first-line treatment and 2-chlorodeoxyadenosine (cladribine-2-CdA) was administered in 31 cases, 19 patients received interferon-alpha (INF-α), splenectomy was performed in 16 cases, and rituximab was used in one. \udResults: Although the highest overall response rate (ORR) was observed in patients receiving 2-CdA upfront, ORRs were comparable in the 2-CdA, INF-α, and splenectomy subgroups. Relapse rates were significantly lower in patients who received first-line 2-CdA. The progression-free survival (PFS) rate with 2-CdA was significantly higher than in patients with INF-α and splenectomy, but we found similar overall survival rates with all three upfront treatment modalities. Infections including tuberculosis were a major problem. \udConclusion: Although purine analogues have improved the ORRs and PFS, there is still much progress to make with regard to overall survival and relapsed/refractory disease in patients with HCL